Sugi Predict

Sugi Predict / Compounds / SCHEMBL209848

SCHEMBL209848

SCHEMBL209848

CN1CCc2nc(Br)sc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.51
▸ RAD52 P43351 2/20 0.40
▸ RECQL P46063 1/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ HPGD P15428 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ F10 P00742 5/20 0.38
▸ OGA O60502 1/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ ALOX15 P16050 1/20 0.36
▸ HRH3 Q9Y5N1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314088 0.89 GRM5 (0.42) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL3309089 0.86 GRM5 (0.39) GRM5RAD52RECQLCYP2C19KDM4E
SCHEMBL9574589 0.85 HRH3 (0.48) GRM5RAD52CYP2C19HPGDNPC1
SCHEMBL8051769 0.81 GRM5 (0.51) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL1252785 0.80 F10 (0.43) GRM5CYP2C19HPGDNPC1CYP1A2
SCHEMBL16870042 0.79 GRM5 (0.50) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL19454341 0.79 GRM5 (0.50) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL13019235 0.79 GRM5 (0.50) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL114205 0.79 RAD52 (0.63) GRM5RAD52RECQLCYP2C19HPGD
SCHEMBL14998845 0.79 GRM5 (0.47) GRM5RAD52RECQLCYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507245-B Preparation method of idosiban and intermediate thereof 江苏丽源医药有限公司 2024-03-19 — — CN claimed
CN-114507245-A Preparation method of idoxaban and intermediate thereof 江苏丽源医药有限公司 2022-05-17 — — CN claimed
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 — — US claimed
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 — — US claimed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
WO-2025075234-A1 NOVEL METHOD FOR PREPARING EDOXABAN 주식회사 파마코스텍 2025-04-10 — — WO disclosed
WO-2024197723-A1 PREPARATION METHOD FOR EDOXABAN TOSILATE 浙江九洲药业股份有限公司 2024-10-03 — — WO disclosed
US-20240124406-A1 INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. 2024-04-18 — — US disclosed
CN-114507245-B Preparation method of idosiban and intermediate thereof 江苏丽源医药有限公司 2024-03-19 — — CN disclosed
CN-114507245-B Preparation method of idosiban and intermediate thereof 江苏丽源医药有限公司 2024-03-19 — — CN disclosed
CN-116761795-A Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof 达纳-法伯癌症研究所股份有限公司 2023-09-15 — — CN disclosed
CN-116332958-A Preparation method of idexaban p-toluenesulfonate 浙江九洲药业股份有限公司 2023-06-27 — — CN disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 — — US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 — — US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 — — US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 — — EP disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed
US-5656637-A SEROTONIN RECEIVER ANTAGONIST; PSYCHOLOGICAL DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 — — US disclosed
US-5424431-A Shows selective agonistic activity for 5-HT3 receptor, useful drug for digestive disorder YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1995-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID PAH, CA4, TET2 GRM5 717/4885RAD52 4769/4885RECQL 4765/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R GRM5 2219/4885RAD52 1613/4885RECQL 23/4885
US-20240124406-A1 INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF TEAD1, TEAD2, TEAD4 GRM5 4083/4885RAD52 4119/4885RECQL 2307/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R GRM5 2219/4885RAD52 1613/4885RECQL 23/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 GRM5 2049/4885RAD52 3887/4885RECQL 3335/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 GRM5 4145/4885RAD52 2924/4885RECQL 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.